Silverback Therapeutics Inc

NASDAQ:SBTX   3:59:51 PM EDT
3.25
+0.04 (+1.25%)
Restructuring / Reorganization, Earnings Announcements

Silverback Therapeutics Updates Strategic Priorities And Reports Fourth Quarter And Full Year 2021 Financial Results

Published: 03/31/2022 20:31 GMT
Silverback Therapeutics Inc (SBTX) - Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results.
Silverback Therapeutics Inc - Estimated Cash Runway Extended Into Second Half of 2026.
Silverback Therapeutics Inc - Silverback to Restructure Workforce to Support Prioritized Development, Reduce Operating Expense, and Extend Cash Runway.
Silverback Therapeutics Inc - Discontinuing Sbt6050 and Sbt6290 Clinical Oncology Programs.
Silverback Therapeutics Inc - Restructure Workforce to Focus Resources on Sbt8230 Program and Discovery Pipeline, Reducing Headcount by 27%.
Silverback Therapeutics Inc - Strategic Realignment to Focus Resources on Sbt8230 for Chronic Hepatitis B Virus (chbv) and Discovery Pipeline.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.47

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.39

More details on our Analysts Page.